Home Cart 0 Sign in  

[ CAS No. 23541-50-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 23541-50-6
Chemical Structure| 23541-50-6
Structure of 23541-50-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 23541-50-6 ]

Related Doc. of [ 23541-50-6 ]

Alternatived Products of [ 23541-50-6 ]

Product Details of [ 23541-50-6 ]

CAS No. :23541-50-6 MDL No. :MFCD04974507
Formula : C27H30ClNO10 Boiling Point : -
Linear Structure Formula :- InChI Key :GUGHGUXZJWAIAS-QQYBVWGSSA-N
M.W : 563.98 Pubchem ID :62770
Synonyms :
Daunomycin hydrochloride;RP 13057 hydrochloride;RP 13057;Ondena;NDC 0082-4155;Daunorubicin (hydrochloride);RP 13057 HCl;Rubidomycin HCl;Daunorubicin HCl;Rubidomycin hydrochloride

Calculated chemistry of [ 23541-50-6 ]

Physicochemical Properties

Num. heavy atoms : 39
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.44
Num. rotatable bonds : 4
Num. H-bond acceptors : 11.0
Num. H-bond donors : 5.0
Molar Refractivity : 138.47
TPSA : 185.84 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -7.87 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 2.63
Log Po/w (WLOGP) : 1.51
Log Po/w (MLOGP) : -1.15
Log Po/w (SILICOS-IT) : 1.77
Consensus Log Po/w : 0.95

Druglikeness

Lipinski : 2.0
Ghose : None
Veber : 1.0
Egan : 1.0
Muegge : 2.0
Bioavailability Score : 0.17

Water Solubility

Log S (ESOL) : -4.96
Solubility : 0.00622 mg/ml ; 0.000011 mol/l
Class : Moderately soluble
Log S (Ali) : -6.18
Solubility : 0.00037 mg/ml ; 0.000000656 mol/l
Class : Poorly soluble
Log S (SILICOS-IT) : -4.04
Solubility : 0.0516 mg/ml ; 0.0000914 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 1.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 5.84

Safety of [ 23541-50-6 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P261-P281-P301+P310 UN#:2811
Hazard Statements:H301-H334-H351 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 23541-50-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 23541-50-6 ]
  • Downstream synthetic route of [ 23541-50-6 ]

[ 23541-50-6 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 110925-43-4 ]
  • [ 553-53-7 ]
  • [ 23541-50-6 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 2
  • [ 110925-39-8 ]
  • [ 54-85-3 ]
  • [ 23541-50-6 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 3
  • [ 193743-47-4 ]
  • [ 23541-50-6 ]
Reference: [1] Patent: US6677309, 2004, B1, . Location in patent: Page/Page column 17; 18; 56
  • 4
  • [ 36508-71-1 ]
  • [ 23541-50-6 ]
  • [ 613-94-5 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 5
  • [ 110925-43-4 ]
  • [ 553-53-7 ]
  • [ 23541-50-6 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 6
  • [ 110925-39-8 ]
  • [ 54-85-3 ]
  • [ 23541-50-6 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 7
  • [ 110925-32-1 ]
  • [ 23541-50-6 ]
  • [ 5351-17-7 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 8
  • [ 66996-57-4 ]
  • [ 23541-50-6 ]
  • [ 5351-23-5 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 9
  • [ 110925-36-5 ]
  • [ 23541-50-6 ]
  • [ 110925-44-5 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 10
  • [ 110925-37-6 ]
  • [ 19827-16-8 ]
  • [ 23541-50-6 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 6, p. 398 - 402[2] Khimiko-Farmatsevticheskii Zhurnal, 1987, vol. 21, # 6, p. 663 - 667
  • 11
  • [ 23541-50-6 ]
  • [ 25316-40-9 ]
Reference: [1] Carbohydrate Research, 1988, vol. 184, p. 231 - 235
Same Skeleton Products
Historical Records